Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind and VETS to support Phase 3 recruitment for HLP003 in MDD and expand veteran mental health outreach, aligning with a recent Executive Order.
Key takeaways
Helus Pharma partners with TARA Mind and VETS for PARADIGM HLP003 Phase 3 recruitment in MDD.
Partnership targets veteran communities to boost trial participation and mental health awareness.
Aligns with President Trump’s April 18, 2026 Executive Order on accelerating mental health treatments.
HLP003 has FDA Breakthrough Therapy Designation for adjunctive MDD treatment.
Eric So, Interim CEO, highlights support for recruitment and Executive Order priorities.